New hope for rare cancers: Two-Drug combo enters key trial
NCT ID NCT03333616
Summary
This study is testing whether a combination of two immunotherapy drugs, nivolumab and ipilimumab, can help control advanced, rare cancers of the urinary and reproductive systems. It is for adults whose cancer has spread and who have few other treatment options. The main goal is to see if the treatment shrinks tumors and for how long, while closely monitoring side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENITOURINARY CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02115, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
University of California, San Diego Moores Cancer Center
La Jolla, California, 92093, United States
-
Winship Cancer Institute, Emory University
Atlanta, Georgia, 30322, United States
Conditions
Explore the condition pages connected to this study.